Cargando…

Targeting the UPS as therapy in multiple myeloma

The coordinated regulation of cellular protein synthesis and degradation is essential for normal cellular functioning. The ubiquitin proteasome system mediates the intracellular protein degradation that is required for normal cellular homeostasis. The 26S proteasome is a multi-enzyme protease that d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Dharminder, Bianchi, Giada, Anderson, Kenneth C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582802/ https://www.ncbi.nlm.nih.gov/pubmed/19007431 http://dx.doi.org/10.1186/1471-2091-9-S1-S1

Ejemplares similares

Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2020)

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
por: Moscvin, Maria, et al.
Publicado: (2021)

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
por: Ray, Arghya, et al.
Publicado: (2019)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Targeted therapy of multiple myeloma
por: Zhou, Shan, et al.
Publicado: (2021)

A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
por: Das, Deepika Sharma, et al.
Publicado: (2016)

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2020)

Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Ho, Matthew, et al.
Publicado: (2022)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
por: Chauhan, Dharminder, et al.
Publicado: (2011)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Multiple myeloma: the (r)evolution of current therapy and a glance into the future
por: Gulla', Annamaria, et al.
Publicado: (2020)

Adhesion molecules in multiple myeloma oncogenesis and targeted therapy
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
por: Crawford, Lisa J., et al.
Publicado: (2020)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival
por: Chen, Tianzeng, et al.
Publicado: (2022)

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2014)

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
por: Theodoropoulos, Nicholas, et al.
Publicado: (2020)

Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Chen, Tianzeng, et al.
Publicado: (2020)

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
por: Suzuki, Rikio, et al.
Publicado: (2014)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

New therapies in multiple myeloma
por: Merchionne, F., et al.
Publicado: (2007)

Diagnosis and therapy of multiple myeloma
por: Palumbo, Antonio, et al.
Publicado: (2013)

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
por: Song, Yan, et al.
Publicado: (2021)

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
por: Larsen, Jeremy T., et al.
Publicado: (2015)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
por: Johnstone, Megan, et al.
Publicado: (2022)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a2dupm04mimq59p29u9mf9gqdp